Fixní kombinace elbasvir a grazoprevir

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English	Fixed combination of elbasvir and grazoprevir
Authors	HUSA Petr
Year of publication	2017
Type	Article in Periodical
Magazine / Source	Remedia
MU Faculty or unit	Faculty of Medicine
Citation
Field	Epidemiology, infectious diseases and clinical immunology
Keywords	chronic hepatitis C; directly acting antivirals; elbasvir; grazoprevir
Description	Chronic hepatitis C therapy using directly acting antivirals (DAA) has high efficacy (up to 100%), minimum contraindications plus an extraordinarily favorable safety profile. Fixed combination of elbasvir and grazoprevir represents a newly available, highly effective variant of this therapy, indicated for patients infected with hepatitis C virus (HCV), genotypes 1 or 4. Elbasvir (EBR) is a NS5A inhibitor of the second wave of the 1st generation; grazoprevir (GZR) is a protease inhibitor of the 2nd generation. The preparation Zepatier includes 50 mg of EBR and 100 mg of GZR. The standard dose is one tablet daily.